Uncategorized Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health by Mbio2018|Published September 1, 2018 https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
Published November 1, 2018 Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City
Published April 9, 2024 Manhattan BioSolutions, Inc. Announces Collaborative Poster Presentation on Novel FGFR4-Targeted ADC at AACR Annual Meeting 2024
Published June 1, 2018 Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University
Published May 15, 2023 Manhattan BioSolutions, Inc. Enters into License Option Agreement with Wisconsin Alumni Research Foundation (WARF) for the RNA Nuclease Technology
